Research peptides
ARA-290
ARA-290, also known as cibinetide or pyroglutamate helix B surface peptide, is an 11-amino-acid synthetic peptide patterned on the exposed face of helix B in erythropoietin. The aim behind it was to keep erythropoietin's tissue-protective signaling while leaving out its stimulation of red blood cell production.
- Container
- Glass vial, crimp seal, flip-top cap
- Storage
- -20 °C, desiccated
- Paperwork
- Lot certificate (HPLC + mass spec) shown before you pay
Lot certificates
You’ll see American Peptides on the lab’s copy. They’re our supplier.
- 10 mg, lot ARA2901-0803: 99.72% purity (RP-HPLC), 10.86 mg measured, identity confirmed by mass spec. Issued 2026-08-28 by Bioviridian Inc.. Verify certificate COA7616
Our vials are filled from lots made by our supplier, American Peptides, and tested by Bioviridian Inc.The laboratory’s original certificate lists American Peptides as the vendor. Look up the code at bioviridians.com to check it.
What researchers study it for
- Small fiber neuropathy in people with sarcoidosis
- Nerve symptoms and metabolic measures in type 2 diabetes
- Measuring nerve fibers in the cornea
- Macular edema in diabetes
- Rodent models of nerve and tissue damage
How it is thought to work
The peptide is characterized as a selective agonist of the so-called innate repair receptor, a pairing of the erythropoietin receptor with the beta common receptor (CD131), which is said to switch on anti-inflammatory and repair pathways. In mice with nerve injury, it eased allodynia in normal animals but not in those missing the beta common receptor. Most published work traces back to one research network connected with the company developing it.
Where the research stands
Small phase 2 trials; no approved product. The human evidence consists of a few modest phase 2 studies, one in people with sarcoidosis-related nerve damage and another in type 2 diabetes, each lasting 28 days and tracking symptom scores plus nerve fiber counts in the cornea. Searching Drugs@FDA turned up nothing approved.
Sources
- Brines M, et al. (2008). Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proceedings of the National Academy of Sciences of the United States of America.
- Dahan A, et al. (2016). Targeting the innate repair receptor to treat neuropathy. Pain Reports.
- Culver DA, et al. (2017). Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Investigative Ophthalmology & Visual Science.
- Brines M, et al. (2015). ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Molecular Medicine.
For laboratory research use only. Not a drug, food, supplement or cosmetic; not for human or veterinary use. Nothing on this page is medical advice or a usage guide.